In subkutanen Forschungsprotokollen werden typischerweise Dosen von 1 bis 4 mg pro Anwendung eingesetzt, mit einer Frequenz von 2 bis 3 Mal pro Woche
This dual-route flexibility makes KPV more practical for protocols where injection compliance is a concern
Ribas GS, Vargas CR, Wajner M
PROMISING POTENTIAL GLP-1RAs offer a promising outlook as transformative therapies in glycemic control, weight management, neuroprotection, and cardiovascular and renal protection
Result Literature search After searching three databases, including PubMed, Embase, and Cochrane Library, a total of 1127 reports were identified (368 from PubMed, 630 from Embase, and 129 from Cochrane Library)